TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.

M Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.